Initial low dose of dacomitinib for first-line treatment of patients with EGFR exon 21 mutated non-small cell lung cancer.

e21083Background: Dacomitinib showed superior efficacy for patients with epidermal growth factor receptor (EGFR) sensitive mutations as compared to that of gefitinib, especially for those harboring...